NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immuneering Corporation (IMRX) Stock Analysis

Immuneering Corporation (IMRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMRX

$3.74

+$0.01 (+0.27%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMRX with… →

IMRX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.73
Previous Close
$3.73
Day's Range
3.72–3.80
52-Week Range
3.38–8.48
Volume
481.86K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.46
Valuation
Market Cap
$241.97M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.93
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$56.02M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.70M
1-Year Return
−36.07%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
684.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMRX closed at $3.74, −36.07% over 1 year.

Immuneering Corporation (IMRX) has a market capitalization of $241.97M.

In fiscal 2025, IMRX reported revenue of $0.00.

IMRX Stock Return by Calendar Year

Immuneering Corporation (IMRX) return since Jul 2021: what $10,000 became

1 year
$10,000 $6,393
−36.07%
5 years
$10,000 $1,432
−85.68%
Since Jul 2021
$10,000 $2,126
−78.74%

If you had invested $10,000 in Immuneering Corporation (IMRX) at the close on July 30, 2021, the earliest close on record here, it would have been worth $2,126 at the close on October 21, 2026: −78.74% in total, −25.64% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.16%
2025+199.09%
2024−70.07%
2023+51.55%
2022−70.01%
2021 (partial year)−8.07%

As of October 21, 2026.

IMRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$56.02M—
2024$0.00−$61.04M—
2023$0.00−$53.47M—
2022$316.95K−$50.51M−15,937.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$59.38M−$56.02M—
2024$0.00—−$64.07M−$61.04M—
2023$0.00$0.00−$58.41M−$53.47M—
2022$316.95K$158.83K−$51.75M−$50.51M−15,937.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immuneering Corporation (IMRX) carries a market capitalisation of $241.97M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 57.

The 52-week range on file runs from $3.38 to $8.48. The most recent close on file for IMRX is $3.74, dated October 21, 2026. That is +$0.01 (+0.27%) against the previous close. The latest close sits 10.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $56.02M. Trailing earnings per share are −0.93.

Across the 4 fiscal years on file, revenue moves from $316.95K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.46. Daily returns over the trailing 5 years annualize to a volatility of 110.71%. The trailing one-year total return is −36.07%. Measured over 5 years, that is −32.21% a year compounded.

Growth & Income

The record shows no dividend for IMRX.

So far in 2026 the total return is −43.16%. Across the complete calendar years on file, 2025 returned +199.09% and 2024 returned −70.07%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Immuneering Corporation (IMRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immuneering Corporation IMRX $241.97M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immuneering Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immuneering Corporation

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Visit website →